RxDoctor Payments Data

Lucian Neville, MD

Cardiovascular Disease · Springfield, MANPI 1194131599

Payments from drug & device makers

$18,331in general payments, 2019–2025

Across 203 payments — averaging $90.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Abbott$7K
  • Medtronic$1K
  • Novartis$781
  • E.r. Squibb & Sons, L.L.C.$444
  • Medical Device Business Services, Inc.$348
  • plus $2K from 21 others

What the payments were for

  • Grants$9,99054%
  • Food & beverage$6,65436%
  • Education$1,6869%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,331 in reported general payments places this provider in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$61,484
Medicare patients
380
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban356$474,071
XareltoRivaroxaban101$126,170
EntrestoSacubitril/Valsartan41$51,274
MultaqDronedarone Hcl16$29,348
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$6,784
Metoprolol Succinate230$6,312
Flecainide Acetate83$5,359
Amiodarone Hcl62$2,431
Carvedilol74$1,225
Rosuvastatin Calcium40$1,157
Atorvastatin Calcium57$1,076
Dilt-XrDiltiazem Hcl24$954
Ezetimibe11$718
Amlodipine Besylate72$703
Metoprolol Tartrate72$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$307$474,071356 claims
Johnson & JohnsonXarelto$194$126,170101 claims
NovartisEntresto$781$51,27441 claims
Sanofi-aventis U.S. LLCMultaq$104$29,34816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →